Distressed and special situations. US and Europe. Five minutes.

Overnight

Sangamo's auction produced one winner and a lot of contingency. Sangamo Therapeutics filed Chapter 11 in Delaware on 23 June, case 26-10989. On 12 August it concluded a court-supervised auction under section 363. On 25 August it signed the asset purchase agreement with PTC Therapeutics.

The assets are ST-920, isaralgagene civaparvovec, a one-time AAV gene therapy for Fabry disease.

Source: Sangamo Therapeutics, Form 8-K, filed 28 August 2026

The structure

Read where the money actually sits.

So the headline is $211m and the part payable at closing is $111m. Everything above that turns on a regulatory outcome the estate does not control and cannot influence after closing.

Even the $111m is not yet certain. The sale is not approved. It needs a Sale Order, and the hearing is scheduled for Thursday 10 September. The APA also terminates automatically if a Competing Transaction is consummated, so the agreement itself contemplates that someone else may still turn up.

For a creditor modelling recovery, that distinction is the whole exercise. A milestone payable to an estate that will have been wound up long before the FDA decides is a different asset from cash, and it is not worth its face.

The auction is the other thing worth sitting with. A court-supervised 363 process ran from the June petition to the 12 August conclusion and produced PTC as successful bidder. We do not know from this document how many parties bid, whether there was a stalking horse, or what the overbid increments were. Those facts are on the docket and not in the filing, and we will not write that PTC was the only bidder until a document says so.

Separately, Nasdaq denied the Company's request to continue its listing.

Europe desk

France, 3 September: 159 collective-proceeding notices, and not one safeguard.

Zero. On the 4th there were four out of 884. On the 3rd there were none out of 159.

A rescue procedure that appears zero to four times a day, against fifty to two hundred and eighty liquidations, is not a rescue regime. It is an exception that exists so people can say it exists.

Source: BODACC annonces commerciales, publication of 3 September 2026, 159 records, classified on the structured jugement.nature field.

The take

Opinion.

Contingent consideration is how a seller makes a number look bigger and a buyer makes a risk look smaller. Both get what they want and the creditor gets the residual.

The discipline is to model the certain cash, treat every milestone as an option with a strike you do not control, and then ask whether the recovery still clears. On Sangamo the answer is probably yes. On the next one it will not be, and the press release will read exactly the same.

The call

Sangamo Therapeutics, No. 26-10989 (Bankr. D. Del.) The PTC transaction closes on the stated $111m cash terms, with no material reduction to the closing consideration. Resolves by 31 January 2027. Confidence: medium. Basis: an auction has already concluded and the APA is signed; the risk is closing conditions and the Sale Order, not price. What would break it: a Competing Transaction, which the APA expressly contemplates, or the Court declining to approve on 10 September.

Parhurst is not investment advice. No price targets. Every item above links to the public document it came from. Corrections run at the top of the next issue, named.